What Дарзалекс treats: Main Uses and Benefits

Daratumumab (Дарзалекс) is a specialized therapy used across multiple clinical settings to manage serious blood conditions. Its therapeutic areas of use relate to its specific clinical applications.

The medicine is commonly used to treat Multiple Myeloma, High-Risk Smouldering Multiple Myeloma, and Systemic Light Chain (AL) Amyloidosis. It is applied in clinical settings that involve acute or unstable symptom patterns, helping address symptom clusters that create noticeable physiological strain and systemic imbalance.

The benefit of this therapy provides support that helps ease the overall symptom burden by managing the underlying malignant plasma cell population. It is frequently applied during phases when symptoms become more noticeable, where its use assists with maintaining a sense of stability and contributing to improved comfort during symptomatic periods.

“The therapy is relevant for managing symptoms that interfere with daily comfort and is used when additional symptomatic support is needed.”

Quick Summary: Focus on Disease Progression Activity The therapy is relevant for conditions characterized by periods of heightened symptoms, and it helps address symptom clusters related to malignant cell proliferation. It assists with maintaining functional stability and contributing to a longer period of disease control.

Regulatory References

1. European Medicines Agency (EMA) overview of Darzalex

Who Can and Cannot Use Darzalex (Daratumumab)?

Official regulatory documents define the specific populations eligible for the use of Daratumumab, as well as groups for whom use is prohibited or restricted.

Absolute Contraindication

Use is contraindicated in patients with a history of severe hypersensitivity, such as anaphylactic reactions, to daratumumab or any components within the medicine's formulation [Source: FDA/EMA SmPC].

Age-Related and Specific Population Rules

Classification	Eligibility Rule (Official Labeling)
Approved Age Group	The medicine is indicated for adult patients (18 years of age) [Source: EMA SmPC].
Pediatric Use	Safety and efficacy have not been established in the pediatric population (lt 18 years) [Source: EMA SmPC].
Pregnancy	Not recommended; based on its mechanism, it can cause fetal harm [Source: FDA Labeling].
Lactation	Breastfeeding is not recommended during treatment [Source: EMA SmPC].
Hepatic Impairment	No dose adjustment is necessary for mild impairment. The drug has not been studied in moderate or severe impairment [Source: NIH/PMC].
Renal Impairment	No dosage adjustment is necessary for patients with renal impairment [Source: EMA SmPC].

Conditional Use Requirement

Females of reproductive potential must use effective contraception throughout therapy and for a minimum of 3 months after the final dose of the medicine [Source: FDA Labeling]. Additionally, use is not recommended in AL Amyloidosis patients with NYHA Class IIIB or Class IV cardiac disease.

Official Interaction Profile

The interaction profile of daratumumab is distinct from small-molecule drugs. As a monoclonal antibody, it is not anticipated to impact the metabolism of co-administered medicines via the cytochrome P450 enzyme system or small-molecule transport systems. No formal pharmacokinetic interactions are documented in regulatory labels.

Interaction Classifications

Classification	Official Regulatory Finding
Pharmacodynamic Interaction	Additive risk of neutropenia/thrombocytopenia with myelosuppressive agents.
Combination Restriction	Co-administration with Live Vaccines is restricted.
Procedural Constraint	Documented interference with blood-typing and myeloma-monitoring tests.

Official labels note an additive pharmacodynamic interaction when the medicine is combined with other myelosuppressive agents, such as certain proteasome inhibitors or immunomodulatory drugs. This co-administration may increase the severity of blood cell count suppression, requiring periodic monitoring.

A critical, officially documented interaction is the binding to CD38 on red blood cells, which causes interference with blood compatibility testing (Indirect Coombs Test/cross-matching). A mandatory procedural constraint is required: blood bank personnel must be informed of treatment before transfusion. The drug also interferes with myeloma monitoring tests, including Serum Protein Electrophoresis and Immunofixation Electrophoresis.

The pharmacodynamic mechanism of daratumumab involves two core actions that result in the targeted reduction of CD38-expressing cells.

Targeted Lysis and Clearance Mechanisms

This domain covers the primary, multifaceted cytotoxic action of the antibody, which is directed against the CD38 glycoprotein on the surface of the targeted cell population. Daratumumab triggers cell death through three distinct Fc-dependent mechanisms: it recruits immune cells like Natural Killer ( NK) cells and Macrophages to destroy the target cell ( ADCC and ADCP), and it activates the Complement System ( CDC) to puncture the cell membrane. This cascade leads to CD38-positive cell cytoreduction through the combined processes of destruction and clearance from the systemic circulation and tissues.

Immunomodulation and T Cell Enhancement

The drug also influences the immune environment by targeting CD38 receptors on certain immune cells, specifically immunosuppressive Regulatory T cells ( T regs). By eliminating these inhibitory cells, daratumumab leads to the disinhibition of other immune components, such as CD8^+ T cells. This process contributes to the activation and proliferation of CD8^+ T cells, resulting in augmented anti-tumor immune activity within the microenvironment.

The use of Daratumumab (Darzalex or Darzalex Faspro) follows strict, multi-phased protocols. The medicine is administered only by a healthcare professional in a clinical setting.

Administration Scope

The medicine is available in two distinct forms with corresponding administration guidelines:

Route of Administration	Dosing Rule	Frequency Pattern (General)
Intravenous (IV) Infusion	16 mg/kg of actual body weight.	Phased (Weekly > Bi-weekly > Monthly)
Subcutaneous (SC) Injection	1,800 mg fixed dose (with hyaluronidase).	Phased (Weekly > Bi-weekly > Monthly)

Procedural and Schedule Details

Dosing Schedule: The treatment follows an intensive initial period (Induction), typically lasting 6–9 weeks with weekly administrations, which then transitions to a less frequent schedule (e.g., every two or three weeks). This is followed by a maintenance phase of administration once every four weeks that may continue until disease progression.

Special Procedural Conditions:

• Concomitant Medications: Mandatory pre-medications (including corticosteroids, antihistamines, and antipyretics) are required before each dose. Post-medications are also required, usually on the day following administration.
• IV Preparation: The IV concentrate must be diluted in 0.9% Sodium Chloride Injection, USP, prior to infusion, and the initial 16 mg/kg dose may be split over two consecutive days to manage the infusion time.
• SC Administration: The fixed-dose subcutaneous injection is administered into the abdomen over approximately 3–5 minutes, and injection sites must be rotated.
• Missed Dose: If a dose is missed, the dose is administered as soon as possible and the schedule adjusted to maintain the correct dosing interval.

This structural adherence to specific routes, weight-based or fixed dosing, and the phased frequency pattern defines the protocol for the product's use.

Research evidence / Overview of studies for Дарзалекс

The research on Darzalex (daratumumab) is built upon major clinical trials, primarily Randomized Controlled Trials (RCTs). These studies compare treatment regimens with and without daratumumab to evaluate measured outcomes in patient groups. This overview summarizes the structure of that evidence, following the guidance provided by regulatory bodies and scientific literature.

---

1. Evidence for Use in Multiple Myeloma (MM)

Research examined the use of Darzalex for MM in large-scale international Phase 3 RCTs, monitoring adult patients newly diagnosed or with relapsed or refractory disease. Key outcomes monitored were Progression-Free Survival (PFS) and Overall Survival (OS). Studies also explored response depth, including Minimal Residual Disease (MRD) negativity, which are technical biomarkers that were measured in studies. Findings describe measured outcomes related to survival and response rates. The long-term data tracking overall survival for some newer combinations are still accumulating and being monitored.

---

2. Evidence for Use in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Research examined the use of daratumumab in HR-SMM, a precursor condition, via a major Phase 3 RCT. The primary outcome was the time until the disease progressed to active Multiple Myeloma or death. The studies monitored patient groups over defined time intervals. Existing regulatory research is concentrated only on the defined "high-risk" subset, providing limited information for intermediate- or low-risk categories.

---

3. Evidence for Use in Systemic Light Chain (AL) Amyloidosis

The use of Darzalex in AL Amyloidosis was studied in a major Phase 3 RCT. Researchers monitored a composite endpoint called Major Organ Deterioration Progression-Free Survival (MOD-PFS), as well as Overall Survival (OS) and Hematologic Response. However, the trial protocols excluded patients with the most severe cardiac dysfunction (such as NYHA Class IIIB or IV), meaning data for this specific, highly compromised subgroup remain insufficient in the main body of evidence.

---

4. Study Limitations and Unanswered Questions

The current evidence contains clear limitations. The follow-up durations were limited in some studies, and the results apply only to the populations studied. Data for patients with complex pre-existing health issues, such as specific kidney or liver impairment, are insufficient. Additionally, research describing the use of Darzalex for pediatric populations has not been established.

Common questions about Дарзалекс (FAQ)

---

Q: What is Pregabalin used to treat?

According to official regulatory documents, Pregabalin is approved for the management of certain types of neuropathic pain, including pain associated with diabetic peripheral neuropathy and spinal cord injury, as well as postherpetic neuralgia and fibromyalgia. It is also indicated to be taken alongside other medications (adjunctive therapy) to treat partial-onset seizures in adults and certain pediatric patients.

---

Q: Can I take Pregabalin if I have kidney problems?

Official product information indicates that dose adjustments are typically required for adults who have reduced kidney function (renal impairment). The specific dosage depends on a measure of the kidney's clearance function. For this reason, regulatory documents specify that the prescribing healthcare provider must review a patient’s kidney status.

---

Q: Does Pregabalin cause sleepiness or dizziness?

Official information indicates that dizziness and somnolence (sleepiness) are reported as common adverse reactions associated with the use of Pregabalin. Due to these potential effects, the regulatory label warns that this medication may impair a patient's ability to safely drive or operate heavy machinery.

---

Q: Can I stop taking Pregabalin suddenly?

Regulatory documents advise against abrupt discontinuation of Pregabalin. The label typically recommends that the dose be reduced gradually over a minimum period of 1 week to minimize the potential risk of withdrawal symptoms, which can include headache, insomnia, nausea, or anxiety. Discontinuing gradually is advised because abrupt stopping may increase seizure frequency, particularly in patients with seizure disorders.

---

Q: Does Pregabalin cause weight gain or swelling?

Official product information identifies weight gain and peripheral edema (swelling, particularly in the arms and legs) as common adverse reactions. The regulatory label indicates that caution should be exercised when Pregabalin is administered alongside certain anti-diabetic medications.

---

Q: Can I drink alcohol while taking Pregabalin?

The regulatory label specifies that Pregabalin should be used with caution when taken with any Central Nervous System (CNS) depressants, including alcohol. This is because combining Pregabalin with CNS depressants may increase the risk of serious side effects such as respiratory depression (slowed or shallow breathing).

---

Q: Is Pregabalin safe for children?

In the United States, official documents indicate that Pregabalin is specifically approved as an add-on therapy for partial-onset seizures in pediatric patients who are 1 month of age and older. For other specified indications, such as neuropathic pain or fibromyalgia, the safety and effectiveness have not yet been established for pediatric patients.

---

Storage and Disposal Requirements for Darzalex (Daratumumab)

The Darzalex concentrate vial must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F to 46 F) and must be protected from light by remaining in its original carton. It is strictly prohibited to freeze the concentrate or the diluted solution. The medicine must also be kept out of the sight and reach of children.

Storage of Prepared Solution

After dilution, the solution for infusion has limited stability. It can be stored for up to 24 hours when refrigerated at 2 C to 8 C and protected from light. If stored at room temperature (15 C to 25 C), the total time from preparation until the end of the infusion must not exceed 15 hours. The diluted solution must not be stored for reuse.

Disposal

Any unused Darzalex product, or waste material resulting from its use, must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.